Using insurance claims data collected between 2011 and 2024, the researchers compared women who continued taking GLP-1 medications into the first trimester with women who stopped the medications after becoming pregnant
Buse JB, Garber A, Rosenstock J, Schmidt WE, Brett JH, Videbaek N, et al
GLP-1 receptor agonists slow gastric emptying and intestinal transit as part of their mechanism of action, which can lead to constipation in more than 1 in 10 people taking higher doses for weight management
It has the potential to offer a more favorable side effect profile, reducing the gastrointestinal side effects commonly seen with incretin-based therapies
Chromogranin A in the human gastrointestinal tract: an immunocytochemical study with region-specific antibodies